Headlines of the Future: Decoding Healthy Aging


How can advancements in science and medicine make it possible for individuals to enjoy greater health and activity in their later years? For health leaders and organizations such as the Global Coalition on Aging, ensuring individuals can truly shine in their "Golden Years" is a matter of revisiting education and communication strategies, advancing digital health technologies and expanding access to healthcare innovation.

You can find the transcript of this episode.

In this episode of Headlines of the Future, we discuss the latest advancements in the promotion and adoption of healthy aging with Dr. Michael Hodin, CEO of the Global Coalition on Aging and Dr. Michael Devoy, Executive Vice President for Medical Affairs and Pharmacovigilance for the Pharmaceuticals Division at Bayer.

A portrait of a man in a suit and tie.
We have at our fingertips the possibility of great things over the next couple of decades, but there's some very critical public policy reforms that are essential, not least to ensure proper investment in health”.
Michael W. Hodin

Michael W. Hodin, Ph.D. is CEO of the Global Coalition on Aging, Managing Partner at High Lantern Group, and a Fellow at Oxford University’s Harris Manchester College. He has spoken internationally on the topic of aging, including at G20, APEC, Davos, and the World Knowledge Forum (WKF). From 1976-80, Mike was Legislative Assistant to Senator Daniel Patrick Moynihan. During this period he was also a Visiting Scholar at Brookings Institution, on U.S. Foreign Economic Policy. He was a senior executive at Pfizer, Inc. for 30 years, where he created and then led its International Public Affairs and Public Policy operations and served on Management Boards for a number of its businesses. Mike is a Member of the Council on Foreign Relations, and from 2010-2013, was Adjunct Senior Fellow with a focus on population aging. In 2013, Mike was invited by then-Committee Chairman Bill Nelson (D-FL) to lead a Members’ Roundtable with the U.S. Senate Special Committee on Aging. Mike was also the recipient of the 2012 Fred D. Thompson Award from the American Federation for Aging Research.

A man in a suit and tie standing in front of a green background.
What's exciting is what's happening there, what we call regenerative medicine, stem cells, therapy, gene therapy, where we really see the potential to intervene in some of these conditions such as heart failure, such as eye disease and reverse. potentially cure and so I think we will, in the next years, start to see some potential innovations, which will now be able to reverse some of these diseases and potentially cure them”.
Dr. Michael Devoy

Dr. Michael Devoy is the Executive Vice President for Medical Affairs and Pharmacovigilance for the Pharmaceuticals Division at Bayer. He is also the Chief Medical Officer of Bayer AG. Dr. Devoy joined the former Schering AG in 2005 as Senior Vice President of Global Medical Development and was appointed to his current position in 2014. Dr. Devoy studied Medicine and Pharmacology at University College London and graduated with a Bachelor of Medicine/Bachelor of Surgery (MB, BS). He is a member of the Royal College of Physicians in London. Dr. Devoy has extensive experience across Clinical Development and International Medical Affairs. His career in the pharmaceutical industry began when he joined Glaxo Group Research in Clinical Pharmacology.


Headlines of the Future is available everywhere you stream your favorite podcasts, or you can listen to it right here. 
Apple Podcast | Spotify | Google Podcasts | Podbean